Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men.
about
Postprandial lipemic and inflammatory responses to high-fat meals: a review of the roles of acute and chronic exerciseNutritional lipidomics: molecular metabolism, analytics, and diagnosticsImpaired-inactivation of FoxO1 contributes to glucose-mediated increases in serum very low-density lipoproteinThe National Niemann-Pick Type C1 Disease Database: correlation of lipid profiles, mutations, and biochemical phenotypes.Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol.High density lipoprotein (HDL) promotes glucose uptake in adipocytes and glycogen synthesis in muscle cells.Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP).Trans-ethnical shift of the risk genotype in the CETP I405V with longevity: a Chinese case-control study and meta-analysis.A reduction of CETP activity, not an increase, is associated with modestly impaired postprandial lipemia and increased HDL-cholesterol in adult asymptomatic womenTriglycerides and heart disease: still a hypothesis?Molecular regulation of HDL metabolism and function: implications for novel therapies.Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal womenHow do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?Obesity and altered glucose metabolism impact HDL composition in CETP transgenic mice: a role for ovarian hormones.Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studiesEffects of 34 risk loci for type 2 diabetes or hyperglycemia on lipoprotein subclasses and their composition in 6,580 nondiabetic Finnish men.Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism.Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD.High-density lipoprotein subclass and particle size in coronary heart disease patients with or without diabetes.Meal frequency differentially alters postprandial triacylglycerol and insulin concentrations in obese womenCardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.Effect of weight loss, independent of change in diet composition, on apolipoprotein AI kinetic in men with metabolic syndrome.Thematic review series: patient-oriented research. What have we learned about HDL metabolism from kinetics studies in humans?Toxic metabolic syndrome associated with HAART.Oral L-Arginine Administration Improves Anthropometric and Biochemical Indices Associated With Cardiovascular Diseases in Obese Patients: A Randomized, Single Blind Placebo Controlled Clinical Trial.The effect of moderate intensity exercise in the postprandial period on the inflammatory response to a high-fat meal: an experimental studyEffect of an isoenergetic traditional Mediterranean diet on apolipoprotein A-I kinetic in men with metabolic syndrome.A patient with a novel homozygous missense mutation in FTO and concomitant nonsense mutation in CETP.Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.Prior exercise and postprandial incretin responses in lean and obese individuals.Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.Egg consumption modulates HDL lipid composition and increases the cholesterol-accepting capacity of serum in metabolic syndrome.Clinical Significance of Determining Plasma MicroRNA33b in Type 2 Diabetic Patients with Dyslipidemia.CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice.Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion.Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.Structural and biophysical insight into cholesteryl ester-transfer protein.
P2860
Q28075762-3CA535FF-B3DC-44DD-A09E-FDFAA0B0FD1FQ28390150-443F7D30-5438-46C5-BD91-889CDD3424A9Q28583188-F95F8EF2-8938-4EE5-8C0C-DC0AB78D2892Q33577880-510954E3-8B29-458E-B214-C76D2DE2A611Q33590777-C1F3F20D-F396-4CE1-8BEF-DC8C261D11A1Q33993200-BF5FBD5A-1A16-49D6-AD21-5D9A684D3EDEQ34008856-8E1527F1-F4CC-4D28-B582-8740D7F75937Q34220871-1CFA1741-B14B-409A-B5E4-EFBEA6CE0AA8Q34973923-68AF24C7-17CD-4E9A-B21C-8F05D37D1966Q35074336-D901FF2D-D79E-4667-AF04-B3AB13F546F2Q35120360-F1D5AA53-43C9-4C94-9160-8548873B1160Q35191066-C824141F-5228-48C5-A5A4-7CCDB57A2ADDQ35590308-85AAE315-694F-4E6D-A3EF-E5BC34B4EACCQ35738372-A477437C-94B4-493B-93EC-D5CD07357CA3Q35747749-7D1BA7C3-616D-4A35-8B65-AE486654450AQ35754362-93E11341-F1B5-4D7C-BC68-F4CBC994DE47Q35797050-763FC10A-2C53-468B-9FAD-D857B87BD4C7Q35958491-842143FF-72E8-4F80-B1ED-A205D7F1C6BAQ36069817-D717694D-2CFC-425C-A92E-F82BC438C461Q36335099-4F787A5B-0B0A-4C16-AF30-B5FBA4BC5823Q36356855-DA833881-2FB3-44F2-9A1D-7C518930222DQ36419283-654EB3CE-A681-4F35-8388-10662AFB8A6DQ36462080-EAF21186-A98E-4082-AF91-20293F77ADA8Q36473656-303F4D50-9B8D-4955-A003-3257E7FE7E85Q36544924-E94ADECA-EEF4-43EC-8CD3-BA3B006311EBQ36569630-B9D1354B-E83A-49DE-AF36-F741524A2B72Q36667997-8B7D841B-14A9-48B1-A99B-D8EA3205E390Q36921867-0ECBB13C-D647-4B4B-A4D5-4A592922DA5BQ36936123-FF51A267-C3FE-41C7-8BD8-3778DED39ED0Q37013499-8BDB8F4B-92DF-4C58-8D21-8377C0DDDDCEQ37185030-CE0739F1-1E44-44C0-BEAD-78616D9739A7Q37311103-E657F916-5E8D-465F-B34F-6D6586B04369Q37353135-726A2784-0C15-484F-A971-E5D1870242A8Q37407021-9732E1AB-F390-4765-A968-C558F74CCDD8Q37420502-FE444B79-3147-4E4C-9DE3-47829952E51DQ37463344-46A89CCF-049E-447B-93EB-BB0DE7F819C4Q37671062-22F136F5-C3B1-4DD4-A3E8-6437FD518AACQ37677573-29ED0864-DBE2-4EEA-920C-AC0F4E56745FQ37772510-A6B9F121-92F6-449A-83CF-E2E0CE1FAEF6Q37905146-8741B56B-3F3C-44D2-9E3C-55F3221A2FEC
P2860
Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Triglyceride enrichment of HDL ...... of HDL apo A-I in healthy men.
@ast
Triglyceride enrichment of HDL ...... of HDL apo A-I in healthy men.
@en
type
label
Triglyceride enrichment of HDL ...... of HDL apo A-I in healthy men.
@ast
Triglyceride enrichment of HDL ...... of HDL apo A-I in healthy men.
@en
prefLabel
Triglyceride enrichment of HDL ...... of HDL apo A-I in healthy men.
@ast
Triglyceride enrichment of HDL ...... of HDL apo A-I in healthy men.
@en
P2093
P2860
P356
P1476
Triglyceride enrichment of HDL ...... of HDL apo A-I in healthy men.
@en
P2093
A Carpentier
B Lamarche
K D Uffelman
P H Barrett
P2860
P304
P356
10.1172/JCI5286
P407
P577
1999-04-01T00:00:00Z